10,/563570 JAP15 Rec'd PCT/PTO 06 JAN 2006

ATTORNEY DOCKET NO. 059742-5001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
David H. WAGNER) Group Art Unit: Unassigned)
Application No.: Unassigned) Examiner: Unassigned
Based on PCT/US2004/021646)
(International Filing Date: July 7, 2004))
)
Filed: Herewith)

For: METHODS FOR PREDICTING DEVELOPMENT

OF AUTO-IMMUNE DISEASES AND TREATMENT OF SAME

Commissioner for Patents
MAIL STOP PATENT APPLICATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

A copy of each listed document is attached. Applicant respectfully requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. An International Search Report citing these documents and setting forth the relevance thereof is also enclosed for the Examiner's consideration.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If it should be determined that the listed document constitutes "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such document. Applicant further reserves the right to take

Revised: 12/5/05

1-WA/2505704.1

10/563570 IAP15 Rec'd PCT/PTO 06 JAN 2006

ATTORNEY DOCKET NO. 059742-5001

appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

ally P. Terg

Registration No. 45,397

Date: <u>January 6, 2006</u>

MORGAN, LEWIS & BOCKIUS LLP 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 (202) 739-3000

Revised: 12/5/05

JAP15 Rec'd PCT/PTO 06 JAN 2006

INFORMATION DISCLOSURE CITATION			059742-5001		Serial Na. U., J. 2055 Based on PCT/US04/021646				
(Use several sheets if necessary)		Applicants David H. WAGNER							
PTO Form 1449			Filing Date	ate Group					
		U.S. PATE	Herewith NT DOCUMENTS		nassigned	1			
*Examiner Initial	Document Number	Date	Name	Class	Sub Class Class		Filing Date		
11									
		FOREIGN PA	TENT DOCUMENTS		<u> </u>				
	Document Number	Date	Country	Class	Sub Class	Translation YES NO			
	-					+			
					<u> </u>				
	OTHER DOCUME	NTS (Including	<u> </u> Author, Title, Date, Pertine	nt Pages E	itc.)				
	Gordon, J.E. et al. R	at xenograft su	rvival in mice treated with	donor-speci	fic transfu				
	CD154 antibody is enhanced by elimination of host Cd4+ cells. TRANSPLANTATION, Volumn 71, Number 2, January 27, 2001, pages 319-327, see entire document.								
					·				
Examiner	niner Date Considered								
Examiner: In through application	citation if not in conform	red, whether or ance and not co	not citation is in conformationsidered. Include copy of	nce with MF this form wi	PEP 609; o	Iraw line mmunica	ation to		

Revised: 12/5/05